Читать книгу Pet-Specific Care for the Veterinary Team - Группа авторов - Страница 284

An owner brings in an Australian shepherd puppy for its initial examination. The breed carries some increased risk relative to the mdr1 mutation for drug sensitivity. Your veterinary team already instructed the owner to bring all paperwork they received from the breeder, and you look for evidence of parental testing for the mdr1 mutation. If no evidence of mdr1 testing was provided but a pedigree or registration is included, you can look up parental health testing on the OFA website (http://ofa.org). If no evidence of parental testing is found, you have the owner contact the breeder to see if they can provide official documentation of mdr1 testing on both parents (i.e., if both parents have been tested clear, the puppies should also be clear). If this is not available by the next puppy visit or the breeder did not perform such testing, you collect a blood sample or cheek swab and submit it to a laboratory for mdr1 mutation testing. mdr1 status is important to document in this breed before prescribing any of the drugs that can cause seizures, coma, and death in pets that have the mutation.

A client presents a 4‐year‐old Abyssinian cat that they feel is having issues with vision. An eye examination shows hyperreflective retinas and attenuation of retinal vessels. You recommend an examination by a veterinary ophthalmologist but also send out a genetic test for the rdAc form of PRA. The genetic test result shows that the cat is affected with this simple autosomal recessive disease.

A client brings you the results of a direct‐to‐consumer multiplex test on their French bulldog which reports that it is homozygous for the sod1 mutation and is “at risk” of developing degenerative myelopathy. You report to the owner that their dog has little to no risk of developing degenerative myelopathy as it has never been documented in the breed and the breed likely lacks other mutations required to cause this complexly inherited genetic disease.